GlobeNewswire Inc.··NaProtara's TARA-002 Sustains 55% Response Rate in Bladder Cancer Trial
Protara Therapeutics reports positive 12-month data from Phase 2 ADVANCED-2 trial of TARA-002 in bladder cancer, with 55% complete response rate and no serious adverse events.
TARAPRTObladder cancerBLA submission